First shot at pan-coronavirus vaccine disappoints in VBI Vaccines study
The first data from a clinical trial of a vaccine designed to protect against many kinds of coronaviruses suggest that efforts to significantly improve over existing Covid-19 shots will be hampered by high levels of immunity that many people already have to the virus.
The results of the 101-person study conducted by VBI Vaccines were disclosed Wednesday morning in a press release. The announcement, which was light on details, said that the pan-coronavirus vaccine boosted antibodies against multiple variants of SARS-CoV-2 as well as coronaviruses that infect bats and pangolins.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.